Generic drugmaker Mylan has been subpoenaed by the Securities and Exchange Commission, which is seeking documents involving “certain related party” transactions.
Mylan disclosed the subpoena, received Sept. 10, in its third-quarter financial report filed with the SEC on Friday.
Mylan said it was cooperating with the SEC’s investigation but didn’t provide more details. “We are unable to predict the outcome of this matter at this time,” the company said in the filing.
The company, which reincorporated in the Netherlands this year but maintains its operational headquarters in Cecil, did not respond to emails seeking comment.
Company spokeswoman Nina Devlin told the Wall Street Journal that the subpoena sought information related to issues raised in a July Journal article concerning real estate deals involving Rodney Piatt, Mylan’s vice chairman and lead independent director.
According to the article, Mylan failed to disclose that two parcels of land for its new headquarters building in Southpointe II, and an adjacent lot, previously had been partly owned by Mr. Piatt. Mylan completed the headquarters building in 2013.
Mylan has said there was no need for disclosure because there were no direct dealings between Mr. Piatt and the company.
Before Mylan bought the land, Mr. Piatt transferred his interest in the parcels for a nominal sum to one of his partners in the development, the newspaper said.
Mr. Piatt, a real estate developer, has been a Mylan director since 2004 and is chairman of the company’s compensation committee.
Patricia Sabatini: PSabatini@post-gazette.com or 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.